Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones
Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.
Stocks · News reference
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Gossamer Bio shares are trading higher after the company announced that it has entered into a securities purchase agreement for a private placement financing to provide up to $250 million in aggregate gross proceeds.
Gossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –– Potential for Up to an Additional $100
8-K filing — Gossamer Bio, Inc. (GOSS)
Filed: 2026-08-21 AccNo: 0001728117-26-000077 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits